PDF herunterladen
CC BY 4.0 · Indian J Med Paediatr Oncol 2024; 45(04): 286-292
DOI: 10.1055/s-0042-1760316
Review Article

Clostridium difficile in Oncology Patients—Review of Diagnosis and Management in the Indian Setting

Parikshit S Prayag
1   Department of Infectious Diseases, Deenanath Mangeshkar Hospital, Pune, Maharashtra, India
,
Sampada A Patwardhan
2   Department of Microbiology, Deenanath Mangeshkar Hospital, Pune, Maharashtra, India
,
Shweta P Panchakshari
1   Department of Infectious Diseases, Deenanath Mangeshkar Hospital, Pune, Maharashtra, India
,
Amrita P Prayag 
3   Department of Research, Deenanath Mangeshkar Hospital, Pune, Maharashtra, India
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Clostridoides (formerly Clostridium) difficile (C. difficile) is a toxin-producing, gram-positive anaerobic bacillus, commonly implicated in antibiotic-associated diarrhea and pseudomembranous colitis. The true burden of C. difficile infection is unclear in India, as it is likely underdiagnosed and underreported. Its incidence is much higher in oncology patients where it can contribute significantly to morbidity and mortality. There are several challenges in the Indian setting, including lack of uniform availability of testing infrastructure, as well as therapy. Oncology patients further present with a unique set of challenges. This article will review the approach to diagnosis and management of C. difficile-associated diarrhea in India, with a focus on oncology patients.

Keywords

Clostridium difficile - gram-positive anaerobic bacillus


Publikationsverlauf

Artikel online veröffentlicht:
01. März 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Lessa FC, Gould CV, McDonald LC. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis 2012; 55 (Suppl 2, Suppl 2): S65-S70
    CrossrefPubMedGoogle Scholar
  • 2 Zhang S, Palazuelos-Munoz S, Balsells EM, Nair H, Chit A, Kyaw MH. Cost of hospital management of Clostridium difficile infection in United States-a meta-analysis and modelling study. BMC Infect Dis 2016; 16 (01) 447
    CrossrefPubMedGoogle Scholar
  • 3 Rodríguez Garzotto A, Mérida García A, Muñoz Unceta N. et al. Risk factors associated with Clostridium difficile infection in adult oncology patients. Support Care Cancer 2015; 23 (06) 1569-1577
    CrossrefPubMedGoogle Scholar
  • 4 Chopra T, Chandrasekar P, Salimnia H, Heilbrun LK, Smith D, Alangaden GJ. Recent epidemiology of Clostridium difficile infection during hematopoietic stem cell transplantation. Clin Transplant 2011; 25 (01) E82-E87
    CrossrefPubMedGoogle Scholar
  • 5 Dhawan B, Chaudhry R. An update on Clostridium difficile infection. Trop Gastroenterol 1997; 18 (04) 149-152
    PubMedGoogle Scholar
  • 6 Chaudhry R, Joshy L, Kumar L, Dhawan B. Changing pattern of Clostridium difficile associated diarrhoea in a tertiary care hospital: a 5 year retrospective study. Indian J Med Res 2008; 127 (04) 377-382
    PubMedGoogle Scholar
  • 7 Gupta U, Yadav RN. Clostridium difficile in hospital patients. Indian J Med Res 1985; 82: 398-401
    PubMedGoogle Scholar
  • 8 Chaudhry R, Sharma N, Gupta N. et al. Nagging presence of Clostridium difficile associated diarrhoea in North India. J Clin Diagn Res 2017; 11 (09) DC06-DC09
    PubMedGoogle Scholar
  • 9 Kannambath R, Biswas R, Mandal J, Vinod KV, Dubashi B, Parameswaran N. Clostridioides difficile diarrhea: an emerging problem in a South Indian Tertiary Care Hospital. J Lab Physicians 2021; 13 (04) 346-352
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 10 McDonald LC, Gerding DN, Johnson S. et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018; 66 (07) e1-e48
    CrossrefPubMedGoogle Scholar
  • 11 Bolton RP, Tait SK, Dear PR, Losowsky MS. Asymptomatic neonatal colonisation by Clostridium difficile. Arch Dis Child 1984; 59 (05) 466-472
    CrossrefPubMedGoogle Scholar
  • 12 Loo VG, Bourgault AM, Poirier L. et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011; 365 (18) 1693-1703
    CrossrefPubMedGoogle Scholar
  • 13 Erb S, Frei R, Strandén AM, Dangel M, Tschudin-Sutter S, Widmer AF. Low sensitivity of fecal toxin A/B enzyme immunoassay for diagnosis of Clostridium difficile infection in immunocompromised patients. Clin Microbiol Infect 2015; 21 (11) 998.e9-998.e15
    CrossrefPubMedGoogle Scholar
  • 14 Johnson S, Lavergne V, Skinner AM. et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis 2021; 73 (05) e1029-e1044
    CrossrefPubMedGoogle Scholar
  • 15 Mikamo H, Tateda K, Yanagihara K. et al. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan. J Infect Chemother 2018; 24 (09) 744-752
    CrossrefPubMedGoogle Scholar
  • 16 Chiu CY, Sarwal A, Feinstein A, Hennessey K. Effective dosage of oral vancomycin in treatment for initial episode of Clostridioides difficile infection: a systematic review and meta-analysis. Antibiotics (Basel) 2019; 8 (04) 173
    CrossrefPubMedGoogle Scholar
  • 17 Pogue JM, DePestel DD, Kaul DR, Khaled Y, Frame DG. Systemic absorption of oral vancomycin in a peripheral blood stem cell transplant patient with severe graft-versus-host disease of the gastrointestinal tract. Transpl Infect Dis 2009; 11 (05) 467-470
    CrossrefPubMedGoogle Scholar
  • 18 McDonald LC, Killgore GE, Thompson A. et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353 (23) 2433-2441
    CrossrefPubMedGoogle Scholar
  • 19 Adler A, Miller-Roll T, Bradenstein R. et al. A national survey of the molecular epidemiology of Clostridium difficile in Israel: the dissemination of the ribotype 027 strain with reduced susceptibility to vancomycin and metronidazole. Diagn Microbiol Infect Dis 2015; 83 (01) 21-24
    CrossrefPubMedGoogle Scholar
  • 20 Freeman J, Vernon J, Morris K. et al; Pan-European Longitudinal Surveillance of Antibiotic Resistance among Prevalent Clostridium difficile Ribotypes' Study Group. Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes. Clin Microbiol Infect 2015; 21 (03) 248.e9-248.e16
    CrossrefPubMedGoogle Scholar
  • 21 Banawas SS. Clostridium difficile infections: a global overview of drug sensitivity and resistance mechanisms. BioMed Res Int 2018; 2018: 8414257
    CrossrefPubMedGoogle Scholar
  • 22 Leeds JA, Sachdeva M, Mullin S, Barnes SW, Ruzin A. In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin. J Antimicrob Chemother 2014; 69 (01) 41-44
    CrossrefPubMedGoogle Scholar
  • 23 Popovic N, Korac M, Nesic Z. et al. Oral teicoplanin versus oral vancomycin for the treatment of severe Clostridium difficile infection: a prospective observational study. Eur J Clin Microbiol Infect Dis 2018; 37 (04) 745-754
    CrossrefPubMedGoogle Scholar
  • 24 Garey KW, Ghantoji SS, Shah DN. et al. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother 2011; 66 (12) 2850-2855
    CrossrefPubMedGoogle Scholar
  • 25 Mullane KM, Miller MA, Weiss K. et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 2011; 53 (05) 440-447
    CrossrefPubMedGoogle Scholar
  • 26 Lee CH, Steiner T, Petrof EO. et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent clostridium difficile infection: a randomized clinical trial. JAMA 2016; 315 (02) 142-149
    CrossrefPubMedGoogle Scholar
  • 27 Saha S, Mara K, Pardi DS, Khanna S. Durability of response to fecal microbiota transplantation after exposure to risk factors for recurrence in patients with Clostridioides difficile infection. Clin Infect Dis 2021; 73 (07) e1706-e1712
    CrossrefPubMedGoogle Scholar
  • 28 Tauxe WM, Dhere T, Ward A, Racsa LD, Varkey JB, Kraft CS. Fecal microbiota transplant protocol for clostridium difficile infection. Lab Med 2015; 46 (01) e19-e23
    CrossrefPubMedGoogle Scholar
  • 29 Kelly CR, Fischer M, Allegretti JR. et al. ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections. Am J Gastroenterol 2021; 116 (06) 1124-1147
    CrossrefPubMedGoogle Scholar
  • 30 Kuon C, Wannier R, Sterken D, Fang MC, Wolf J, Prasad PA. Are antimotility agents safe for use in Clostridioides difficile Infections? Results from an observational study in malignant hematology patients. Mayo Clin Proc Innov Qual Outcomes 2020; 4 (06) 792-800
    CrossrefPubMedGoogle Scholar
  • 31 McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989; 320 (04) 204-210
    CrossrefPubMedGoogle Scholar
  • 32 Kundrapu S, Sunkesula V, Jury LA, Sitzlar BM, Donskey CJ. Daily disinfection of high-touch surfaces in isolation rooms to reduce contamination of healthcare workers' hands. Infect Control Hosp Epidemiol 2012; 33 (10) 1039-1042
    CrossrefPubMedGoogle Scholar
  • 33 Aldeyab MA, Kearney MP, Scott MG. et al. An evaluation of the impact of antibiotic stewardship on reducing the use of high-risk antibiotics and its effect on the incidence of Clostridium difficile infection in hospital settings. J Antimicrob Chemother 2012; 67 (12) 2988-2996
    CrossrefPubMedGoogle Scholar